MARKET

IMTXW

IMTXW

IMMATICS WT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.650
+0.020
+0.76%
Closed 16:00 05/18 EDT
OPEN
2.650
PREV CLOSE
2.630
HIGH
2.650
LOW
2.650
VOLUME
3.04K
TURNOVER
--
52 WEEK HIGH
8.49
52 WEEK LOW
1.670
MARKET CAP
180.40M
P/E (TTM)
13.37
1D
5D
1M
3M
1Y
5Y
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) --   * Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Thera
GlobeNewswire · 08/06/2020 11:00
Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ
Houston, Texas and Tuebingen, Germany, July 09, 2020 -- Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage.
GlobeNewswire · 07/09/2020 11:00
Immatics Announces Completion of Business Combination and Listing on NASDAQ
The combined company was renamed Immatics N.V. Houston, Texas and Tuebingen, Germany, July 2, 2020 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer i...
GlobeNewswire · 07/02/2020 11:00
No Data
Learn about the latest financial forecast of IMTXW. Analyze the recent business situations of IMMATICS WT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
No Data
About IMTXW
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Webull offers kinds of Immatics Equity Warrants Exp 1 July 2025 stock information, including NASDAQ:IMTXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMTXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMTXW stock methods without spending real money on the virtual paper trading platform.